TGD001 for blood clotting disorder
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug, TGD001, for a condition called thrombotic microangiopathy (TMA), where small blood clots form in blood vessels and damage organs. The drug aims to break up clots and improve blood flow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently having a severe episode of TMA
- You agree to use effective birth control for 90 days after the last dose
- You have not had a blood-filtering treatment (plasma exchange) in the last 7 days
- You have no active internal bleeding or recent major bleeding
- You do not have severe uncontrolled high blood pressure, kidney or liver failure, or an active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies patients who have had a stem cell or solid organ transplant and may have a condition called TMA (small blood clots in vessels) or a viral infection. It aims to understand how certain immune system parts (complement and interferon) affect these conditions.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
This trial studies how well a drug called daratumumab works for a rare blood disorder (iTTP) that causes dangerous clots and low platelet counts. Researchers want to understand if this treatment helps patients recover and stay healthy long-term.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
Hear when a new Thrombotic Microangiopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.